BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?

Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.